7169-95-1

Usage

Uses

Used in Pharmaceutical Industry:
6-Bromo-2-Methyl[1,2,4]triazolo[1,5-a]pyridine is used as a pharmaceutical compound for its potential therapeutic applications. Its unique structure allows it to interact with biological targets, making it a promising candidate for the development of new drugs.
Used in Synthetic Chemistry:
6-Bromo-2-Methyl[1,2,4]triazolo[1,5-a]pyridine is used as an intermediate in synthetic chemistry for the synthesis of more complex molecules. Its presence in the molecular structure can be exploited to create a variety of chemical products, including advanced materials and specialty chemicals.
Safety Precautions:
As with all chemicals, handling of 6-Bromo-2-Methyl[1,2,4]triazolo[1,5-a]pyridine should be done wearing appropriate protective gear to prevent exposure. This includes gloves, goggles, and lab coats, as well as working in a well-ventilated area to minimize the risk of inhalation or skin contact.

Upstream product

• 1202704-57-1 (1,2-diamino-5-bromopyridin-1-ium) 2,4,6-trimethylbenzenesulfonate 
• 368-39-8 triethyloxonium fluoroborate 
• 108-24-7 acetic anhydride 
• 1072-97-5 5-bromo-2-pyridylamine 

Downstream Products

• 7169-94-0 2-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-amine 
• 1202701-51-6 C₁₉H₁₈FN₅O₃ 
• 1236325-09-9 (S)-6-(2-hydroxy-2-methylpropyl)-6-isopropyl-3-((S)-1-(4-(2-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl)ethyl)-1,3-oxazinan-2-one 

Relevant academic research and scientific papers

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

Substituted heteroaryl compounds and compositions and uses thereof (by machine translation)

The invention discloses substituted heteroaryl compounds and compositions thereof and their use. The compounds of formula (I) compound or type shown in (I) a compound represented by stereo isomers, tautomers, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or its prodrug. The invention also provides a pharmaceutical composition, the compounds and pharmaceutical compositions can be regulated protein kinase, particularly Aurora kinase and JAK kinase activity, for the prevention, treatment, treatment and reduce protein kinase, in particular JAK kinase activity mediated diseases or disorders. (by machine translation)

OXAZOLIDINONE DERIVATIVE HAVING FUSED RING

The present invention provides a novel antimicrobial drug comprising an oxazolidinone derivative of the formula (I): or a pharmaceutically acceptable salt or solvate thereof; wherein ring A is ring B is a benzene ring optionally substituted with lower alkyl; ring C is an optionally substituted six-membered heterocycle containing at least one nitrogen atom and one to three double bond(s) in the ling wherein the atom at the point of attachment to ring B is a carbon atom; ring D is an optionally substituted five-membered ring containing one or two double bond(s) in the ring; A1 and A2 are independently nitrogen or carbon; m is 0 or 1; R represents H, —NHC(═O)RA, —NHC(═S)RA, —NH-het1, —O-het1, —S-het1, —S(═O)-het1, —S(═O)2-het1, het2, —CONHRA, —OH, lower alkyl, lower alkoxy or lower alkenyl; and het1 and het2 are independently a heterocyclic group; with the proviso that the fused ring C-D is not

CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1

This invention relates to novel compounds of an 11 β-HSD1 inhibitor disclosed herein, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modula

(2S,3S)-3-amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1, 2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: A selective α-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

A series of β-substituted biarylphenylalanine amides were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4) for the treatment of type 2 diabetes. Optimization of the metabolic profile of early analogues led to the discovery of (2S